v3.26.1
SEGMENT REPORTING - Revenue (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
brand
productFamily
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
brand
productFamily
Jun. 30, 2025
USD ($)
Segment reporting        
Number of operating segments | segment     2  
Number of reporting units | segment     2  
Established brand products | brand 20   20  
Product families | productFamily 135   135  
Net Revenues $ 266,044 $ 211,371 $ 503,506 $ 408,493
Cost of sales (excluding depreciation and amortization) 100,158 74,615 193,740 147,652
Research and Development expense 14,747 16,535 25,347 27,099
Selling, general, and administrative expense 91,661 81,771 165,316 158,299
Depreciation and amortization 19,640 23,281 40,559 46,172
Contingent consideration fair value adjustment (622) 1,277 (804) (10,815)
Operating income 40,460 13,892 79,348 40,086
Unrealized gain (loss) on investment in equity securities 741 332 6,494 (589)
Interest expense, net (3,636) (5,438) (7,405) (10,922)
Other (expense)income , net (468) 1,739 (1,119) 1,937
Income Before Income Tax Expense 37,097 10,525 77,318 30,512
Corporate and Unallocated        
Segment reporting        
Net Revenues 0 0 0 0
Cost of sales (excluding depreciation and amortization) 0 0 0 0
Research and Development expense 0 0 0 0
Selling, general, and administrative expense 29,364 29,191 46,308 61,875
Depreciation and amortization 19,640 23,281 40,559 46,172
Contingent consideration fair value adjustment (622) 1,277 (804) (10,815)
Operating income (48,382) (53,749) (86,063) (97,232)
Unrealized gain (loss) on investment in equity securities 741 332 6,494 (589)
Interest expense, net (3,636) (5,438) (7,405) (10,922)
Other (expense)income , net (468) 1,739 (1,119) 1,937
Income Before Income Tax Expense (51,745) (57,116) (88,093) (106,806)
Generics and Other | Operating Segments        
Segment reporting        
Net Revenues 100,656 94,213 209,876 197,253
Cost of sales (excluding depreciation and amortization) 51,398 43,231 110,989 89,732
Research and Development expense 11,186 11,414 18,975 18,002
Selling, general, and administrative expense 1,578 1,389 3,100 2,797
Depreciation and amortization 0 0 0 0
Contingent consideration fair value adjustment 0 0 0 0
Operating income 36,494 38,179 76,812 86,722
Unrealized gain (loss) on investment in equity securities 0 0 0 0
Interest expense, net 0 0 0 0
Other (expense)income , net 0 0 0 0
Income Before Income Tax Expense 36,494 38,179 76,812 86,722
Rare Disease and Brands | Operating Segments        
Segment reporting        
Net Revenues 165,388 117,158 293,630 211,240
Cost of sales (excluding depreciation and amortization) 48,760 31,384 82,751 57,920
Research and Development expense 3,561 5,121 6,372 9,097
Selling, general, and administrative expense 60,719 51,191 115,908 93,627
Depreciation and amortization 0 0 0 0
Contingent consideration fair value adjustment 0 0 0 0
Operating income 52,348 29,462 88,599 50,596
Unrealized gain (loss) on investment in equity securities 0 0 0 0
Interest expense, net 0 0 0 0
Other (expense)income , net 0 0 0 0
Income Before Income Tax Expense $ 52,348 $ 29,462 $ 88,599 $ 50,596